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Abstract
Background: Genomics-based predictors of drug response have the potential to improve outcomes associated
with cancer therapy. Osteosarcoma (OS), the most common primary bone cancer in dogs, is commonly treated
with adjuvant doxorubicin or carboplatin following amputation of the affected limb. We evaluated the use of gene-
expression based models built in an intra- or interspecies manner to predict chemosensitivity and treatment outcome
in canine OS. Models were built and evaluated using microarray gene expression and drug sensitivity data from human
and canine cancer cell lines, and canine OS tumor datasets. The “COXEN” method was utilized to filter gene signatures
between human and dog datasets based on strong co-expression patterns. Models were built using linear discriminant
analysis via the misclassification penalized posterior algorithm.
Results: The best doxorubicin model involved genes identified in human lines that were co-expressed and
trained on canine OS tumor data, which accurately predicted clinical outcome in 73 % of dogs (p = 0.0262,
binomial). The best carboplatin model utilized canine lines for gene identification and model training, with
canine OS tumor data for co-expression. Dogs whose treatment matched our predictions had significantly
better clinical outcomes than those that didn’t (p = 0.0006, Log Rank), and this predictor significantly associated with
longer disease free intervals in a Cox multivariate analysis (hazard ratio = 0.3102, p = 0.0124).
Conclusions: Our data show that intra- and interspecies gene expression models can successfully predict response in
canine OS, which may improve outcome in dogs and serve as pre-clinical validation for similar methods in human
cancer research.
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Background
Recent breakthroughs in cancer genomics have made
the emerging field of personalized medicine not only a
plausible but effective alternative to traditional ap-
proaches to cancer treatment. The discovery of bio-
markers such as the breakpoint cluster region/Abelson
(BCR/ABL) gene in patients with chronic myeloid
leukemia, the Estrogen Receptor (ER) status of breast
cancer patients, and the v-Raf murine sarcoma viral
oncogene homologue B1 (BRAF) mutational status of
melanoma patients has resulted in the development of
effective targeted agents and successful patient stratifica-
tion leading to better clinical outcomes [1]. In the case
of ER and BRAF, their expression has been found to be
prognostic in other tumor types as well, such as ER for
non-small-cell lung cancer and the BRAF V600E mutant
being observed in 45 % of papillary thyroid cancers and
11 % of colorectal cancers, showing the potential for
predictive molecular characteristics to be extrapolated
across histological boundaries [2–5]. Although success
of single biomarkers in predicting response to molecu-
larly targeted agents has been observed, this is not the
case with traditional chemotherapeutics, which are still
heavily used in human and veterinary medicine. Typic-
ally a host of genes involved in processes such as drug
activation, detoxification, DNA-repair, stress responses,
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and others are playing a role in determining chemosensi-
tivity. The use of gene expression prediction signatures
have already begun to be used for the accurate predic-
tion of treatment response in many cancers [6–10]. One
such strategy developed by Lee and Theodorescu was
termed the Co-Expression Extrapolation (COXEN)
method [11]. It combines microarray gene expression
and drug sensitivity data from a reference set to identify
gene signatures that are then extrapolated to a different
dataset for drug sensitivity prediction. This method has
been used to successfully predict in vitro sensitivity as
well as clinical outcome in bladder, breast, and non-
small cell lung cancers [11–16]. It has also been imple-
mented for in silico drug screening and is currently
being employed in a prospective human clinical trial
(NCT01228942) [11, 17].
In the recent past, clinical trials in human lung and
breast cancer with similar strategies of selecting drug
treatment based on gene signatures were suspended due
to faulty preclinical data and improper validation of pre-
dictors, a strong reminder that proper pre-clinical valid-
ation is essential for the continued development of such
methods in the clinic [18, 19]. Advanced companion ani-
mal models that share highly similar cancer genomics
with humans and are routinely treated for spontaneous
tumors in a clinical setting would be an ideal choice for
pre-clinical validation studies.
Canine models of cancer have many advantages for
translational research including a high incidence rate of
spontaneous tumors that are comparable to humans both
biologically and genetically [20, 21]. After the canine gen-
ome was sequenced in 2005, studies have revealed high
similarity between human and canine cancers with respect
to genetic homology, molecular alteration of known cancer
pathways, and amplifications of known oncogenes [22–27].
Compared to rodents, larger body and tumor size in dogs
allows for repeated sampling over time from the same pa-
tient and more tissue for molecular analysis [28]. Veterin-
ary clinical trials are less expensive, can be performed in
the pre-IND setting, typically represent a less pre-treated
population, and due to accelerate progression of canine
cancer can be completed faster than human trials [20, 21].
Canine osteosarcoma (OS) is the most common pri-
mary bone tumor in dogs and has been shown to share
similar molecular alterations with the human disease
[29]. Although limb sparing techniques have recently
been developed for patients with existing orthopedic
problems, canine OS patients are most commonly
treated with amputation of the affected limb following
adjuvant doxorubicin and/or carboplatin. Human and
canine OS respond similarly to treatment and similar
molecular pathways that are differentially expressed
between poor and good responders are found in both
species [30, 31].
The purpose of this study was to investigate the utility
of the COXEN method in an intra- and interspecies
manner between human and canine datasets, specifically
in canine osteosarcoma. The reasons behind this chosen
application of COXEN are three-fold: first, a successful
application of COXEN across species would show the
robustness of this method. Secondly, success of this
study would add strength to the growing evidence that
the canine cancer model can greatly impact human
research, specifically in the new genomics era. Lastly,
considering the wealth of human genomic and pharma-
cologic data available to the public, the potential to ex-
trapolate this information into the veterinary setting
through molecular comparisons of tumors would be ex-
tremely advantageous for the field of canine oncology.
Methods
Cell culture
A panel of 29 canine cancer cell lines used for drug
screening at the Flint Animal Cancer Center (FACC)
were maintained as previously described (Additional file
1: Table S1) [24]. Cell line validation was carried out by
multiplex PCR on genomic DNA to confirm species of
origin of each cell line as previously described [32]. Each
line was additionally analyzed by short tandem repeat
profiling using the Canine Stockmarks genotyping Kit
(Life Technologies) per the manufacturer’s protocol and
as previously described [33].
Drug sensitivity assays
Drug sensitivity data was generated via Alamar Blue
assays for cisplatin (CIS), carboplatin (CARBO), doxo-
rubicin (DOX), and vinblastine (VBL) in the FACC panel
as previously described [24], the only deviations being
48 h of drug incubation and cells were plated in 96 well
plates at a density of 1500 – 5000 cells in 100 uL per
well, depending on growth rate. Experiments were per-
formed at least in triplicate, and medial dose (Dm)
values were calculated.
RNA extraction and determination of integrity
Canine cancer cell lines
RNA from the FACC was extracted using the Qiagen
RNeasy Kit (Qiagen, Valencia, CA) according to manu-
facturer’s protocols. A DNase treatment step using the
RNase-Free DNase Set (Qiagen, Valencia, CA) was
included to ensure RNA purity.
Osteosarcoma tumor samples
RNA from 33 frozen tumor samples was extracted as de-
scribed previously [24]. Yield and integrity for all RNA
samples were calculated using a NanoDrop 1000 spec-
trophotometer (Thermo Scientific, Asheville, NC) and
an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA)
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at the Genomics and Microarray Core at the University of
Colorado Denver. Clinical outcome of patients and drug
treatment data was obtained from the database at the
FACC. All dogs received at least one cycle of drug treat-
ment (one cycle of each drug in the case of combination-
treated dogs) before recurrence of disease in this study.
Tissue collection and data acquisition is done with written
owner consent and is approved through the Institutional
Animal Care and Use committee (IACUC) approval num-
ber 13-4304A. As the performance of our prediction
models were assessed retrospectively ethics were not re-
quired for this current study.
Microarray gene expression analysis
RNA samples for the FACC were hybridized onto Affy-
metrix GeneChip Canine Genome 2.0 arrays (Affyme-
trix, Santa Clara, CA) and microarray analysis was
performed at the Genomics and Microarray Core at the
University of Colorado Denver. Raw microarray data
was preprocessed with the Robust Multi-Array Average
(RMA) algorithm. Information on the availability of the
gene expression data for the different datasets can be
found in the “Availability of Data and Materials” section
of this manuscript.
COXEN method for prediction model building
Standardization of data across species and microarray
platforms
In addition to the normalization across samples in a data-
set that occurs as part of RMA preprocessing, the gene ex-
pression data underwent within gene standardization by
subtracting the mean of a probe across samples and divid-
ing by the standard deviation. This allows genes of differ-
ent mean expression intensity to be an more equal footing
for the differential gene expression analysis and makes the
expression data across microarray platforms more com-
parable to each other, especially in the case of working
between human and canine datasets.
Differential gene expression analysis
Differentially expressed genes (DEGs) in our reference
data sets were identified through either Significance
Analysis of Microarrays (SAM) or t-test. SAM analysis
with a q-value cutoff of 0.1 was used comparing the top
and bottom 20 % of samples in the reference set based
on drug sensitivity. T-tests were run between sensitive
and resistant samples with a q-value cutoff of 0.05 to
identify DEGs. If too few DEGs made the q-value cutoff,
a p-value cutoff < 0.001 was then used.
Probeset matching of gene expression data
We employed four different strategies for matching pro-
besets selected from either the Human Genome U133A
or HT Human Genome U133A array to the GeneChip
Canine Genome 2.0 array.
Best sequence homology
We used the Basic Local Alignment Search Tool (BLAST)
to compare the target sequences of the human probesets
with their canine orthologs and selected the match with the
highest sequence homology. The blastn algorithm was se-
lected for somewhat similar sequences, with word size = 7
and expected threshold = 100. In instances where no canine
ortholog was annotated, an attempt at manual annotation
was performed through sequence alignment using Affyme-
trix, BLAST, and USC genome browser tools. If manual an-
notation proved unsuccessful then the human probeset was
removed from the list of candidates for COXEN analysis.
Best correlative match
This strategy was performed by creating correlation
matrices for both human and canine probesets separ-
ately, and then a 3rd correlation matrix created from
each row of the first two matrices. Because the 3rd
matrix is created from the two original matrices, the ori-
ginal matrices had to be identical in dimensions. To do
this, duplicates were added to the human correlation
matrix to equal the number of probesets mapping to
each gene on the canine matrix. The best match was se-
lected that had the highest concordant expression with
other genes in the signature across species.
Data collapsing by averaging method
We took our list of candidate human PSIDs and their
canine orthologs and in cases where multiples existed
for a given gene on either the human or canine side, the
expression values were averaged. This resulted in col-
lapsing the probeset expression data down to the gene
level, reducing the data for each gene to one human and
matching canine expression value. Manual annotation
was attempted when no annotated canine orthologs
were available.
Data collapsing by maximum variance method
Using the collapseRows function from the R package
“WGCNA” [34] we collapsed the gene expression data
from the probe level down to gene level before differen-
tial gene expression analysis by selecting one representa-
tive probe per gene based on maximum variance
between samples, After collapsing is performed in both
human and canine datasets, genes that were not present
on both arrays were filtered out.
Selecting subset of gene signature with strong concordant
expression
The crucial step in the COXEN method is filtering the
list of DEGs down to those that are most in “tune” with
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your target or test dataset, whether it is human derived
DEGs that are most in tune with canine tumors, or a
specific tumor type like osteosarcoma. A dataset with
similar properties as your target or test set is used in this
process and has been termed the “co-expression set”
(Fig. 1). The selecting of co-expressed genes between the
reference and co-expression datasets was based on pro-
tocols described previously by Lee et al. [11, 35]. Briefly,
a correlation matrix was generated for the expression
data of identified DEGs from the reference set to deter-
mine how the genes in the DEG list correlate to one an-
other. A second correlation matrix is created with the
expression data of those same DEGs pulled out from the
co-expression dataset separately. Then, a 3rd correlation
matrix is created comparing each row of the first two
matrices. Genes with correlation values higher than a
cutoff (90th percentile from a random null distribution
or a p-value cutoff of 0.05) were selected as being
strongly co-expressed between the two data sets. In
other words, the genes that are retained have similar
patterns of correlation with each other in both the refer-
ence and co-expression datasets. This subset of the gene
signature was used for prediction model generation.
MiPP algorithm model generation
Prediction models were generated in Bioconductor
using the Missclassification-Penalized Posteriors
(MiPP) algorithm developed by Soukup, Cho and Lee
[36]. Different classification methods such as linear
discriminant analysis (LDA), logistic regression (LOG),
linear support vector machines (SVMLIN), and radius-
based function support vector machines (SVMRBF)
were evaluated. Model training was performed by split-
ting the training set randomly several times into train-
ing and test sets, and the resultant models are then
tested on more random splits of the data to determine
robustness. The top 3–5 performing models are then
used to predict onto a separate test dataset and the
final posterior probability scores are averaged. The av-
eraged posterior probability score has been termed the
“model score”, where a value below 0.5 would be
considered “resistant” to the drug and values including
0.5 and above would be considered “sensitive”. For in
vivo model building, we identified candidate model
genes in cell line datasets, but built the MiPP models
on tumor panel data sets that were used in the co-
expression step.
Fig. 1 The Co-expression Extrapolation (COXEN) method. Steps 1–3 involve identifying a gene signature that predicts chemosensitivity from the
reference set. Steps 4–5 involve gene expression data from the co-expression set and identifying a subset of the gene signature that shares strong
co-expression with the co-expression set. The resulting genes are candidates in prediction model development in step 6, and the resulting predictions
are compared to actual chemosensitivity or clinical outcome in step 7
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Validation of prediction models
To see how well the prediction models correlated with
actual sensitivity data, we standardized both the poster-
ior probability scores for each sample and the actual
GI50 data by subtracting the mean and dividing by the
standard deviation. A Cox proportional hazards regres-
sion correlation was then performed on the two data
sets, as well as a binomial test based on random coin
tossing for the testing of the models ability to success-
fully call a cell line “sensitive” or “resistant”. For in vivo
models we plotted survival curves based on actual dis-
ease free interval data and the class predictions of “re-
sponder” or “non-responder”. Significant differences in
survival curves were determined by Log Rank test.
Results
Human and canine cancer cell lines are similarly sensitive
to chemotherapy
The two main cell line panels that were used for reference
sets in our prediction model development (Fig. 1) were the
human NCI60 panel and the canine FACC panel (Table 1).
Since drug response and microarray gene expression data
were publicly available for the NCI60 panel, we generated
drug response data in the FACC panel via Alamar Blue cell
viability assays for CARBO, CIS, DOX, and VBL. The
range of log GI50 values between the human and canine
panels were compared and found to be strikingly similar
(Fig. 2a), although the means were significantly different
between species except for with CIS (p = 0.0942, Mann
Whitney test).
Selecting a probeset matching strategy between the
human and canine arrays
We next wanted to compare the genomic similarity of
human and canine cancer cell lines in the context of
drug sensitivity. RNA was extracted from untreated
FACC cell lines and microarray gene expression data
was generated. Thirty-nine differentially-expressed genes
(DEGs) were identified in the NCI60 panel by using the
12 most and least sensitive cell lines to DOX in a SAM
analysis. Since there are roughly twice as many probesets
on the canine microarray chip as the human, and also
on both chips there are often multiple probesets map-
ping to the same gene, it became apparent that a strat-
egy for selecting the best match for the identified DEGs
between species was needed. Three strategies were ini-
tially implemented and tested for matching up the pro-
besets. The strategies named best sequence homology,
data collapsing by averaging, and best correlative match
are explained in full in the Supplemental Methods. Each
strategy was used resulting in a human gene signature
with matching canine data for both a DOX and VBL
analysis. To test which strategy would produce the most
predictive models, each were carried through the
remaining steps of the COXEN analysis (Fig. 1). We
tested a combination of all three probe matching strat-
egies together with the five classification methods and
generated prediction models. Comparing the resulting
sMiPP scores and error rates associated with each model
generated, best sequence homology was selected as an ap-
propriate probeset matching strategy. We found multiple
classification methods to be comparable in terms of
overall performance and selected the commonly used
LDA classification method for the remaining of our
studies (Additional file 2: Table S2). During the refining
process of developing models, however, we incorporated
another probeset matching strategy that was automated
and less time intensive than comparing the sequence
homology of potential probe matches. This new method
(max variance) involved collapsing both the human and
canine array information to the gene level prior to differ-
ential gene expression analysis by selecting one probe
per gene based on maximum variance between samples.
It was performed using the collapseRows function in the
Table 1 Datasets used in study
Datasets # of samples Sample type Tumor types represented Microarray platform/public ID
NCI60 60 Human cancer cell lines Breast, melanoma, central nervous
system, colon, lung, leukemia, ovarian,
prostate, renal
GeneChip Human Genoma U133A
array (GSE5846)
GDSCosteo 10 Human osteosarcoma cell lines
(subset of GDSC panel)
Osteosarcoma GeneChip HT Human Genome U133A
array (E-MTAB-783, ArrayExpress)
FACC 29 Canine cancer cell lines Hemangiosarcoma, histiocytosis, leukemia,
lymphoma, mammary tumor, mast cell,
melanoma, osteosarcoma, soft tissue
sarcoma, transitional cell carcinoma
GeneChip Canine Genome 2.0
array (GSE76126)
FACCosteo 10 Canine osteosarcoma cell lines
(subset of FACC panel)
Osteosarcoma GeneChip Canine Genome 2.0
array (GSE76126)
COS16 16 Canine osteosarcoma tumor
samples
Osteosarcoma GeneChip Canine Genome 2.0 array
(GSE24251)
COS33 33 Canine osteosarcoma tumor
samples
Osteosarcoma GeneChip Canine Genome 2.0
array (GSE76127)
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“WGNCA” R package. We consider both of these
methods as viable options for matching genes across
platforms and used both in our attempts to optimize our
prediction models.
Human and canine cancer cell lines share comparable
genomic profiles of doxorubicin sensitivity
An unsupervised hierarchical cluster analysis was per-
formed using expression data from the 39 NCI60-
derived DEGs for DOX in both sensitive and resistant
NCI60 and FACC cell lines, and we observed that all the
NCI60 samples separated according to DOX sensitivity
(Fig. 2b). Also, 67 % (8/12) of FACC cell lines in the ana-
lysis separated according to sensitivity and interspersed
with human samples, suggesting that human-derived
DEGs are predictive in canine cancer cell lines (Fig. 2b).
A cluster analysis was performed using NCI60-derived
DEGs with the NCI60 panel and a publicly available ca-
nine osteosarcoma tumor panel (COS16, Table 1), where
available samples were originally selected to determine
differential gene expression between extreme groups of
response to DOX (DFI < 100 days versus DFI > 300 days).
The cluster analysis resulted in 92 and 100 % of the
NCI60 and COS16 samples sorting by drug sensitivity,
respectively (Additional file 3: Figure S1A). DEGs were
then derived from the six most and least sensitive sam-
ples to DOX in the FACC panel. When cluster analysis
was performed with FACC and the COS16, 100 % and
86 % of the FACC and COS16 samples sorted by drug
sensitivity, respectively (Additional file 3: Figure S1B).
Taken together, we’ve shown that human and canine
cancer cells respond similarly to chemotherapy and that
Fig. 2 The effect of in vitro human COXEN models on predicting canine cell line sensitivity to doxorubicin or carboplatin. a GI50 ranges of the
human NCI60 panel to 3 chemotherapeutics commonly used for canine osteosarcoma treatment were compared to the GI50 ranges generated
in the canine FACC panel via Alamar Blue assays. b Differentially expressed genes based on sensitivity of NCI60 samples to doxorubicin were
used in the most and least sensitive NCI60 and FACC samples in unsupervised hierarchical clustering. Light green and pink bars refer to sensitive
and resistant samples, respectively. Blue and yellow bars refer to NCI60 and FACC samples, respectively. c & d COXEN predictions of doxorubicin
(c) or carboplatin (d) sensitivity in the FACC cells from NCI60-trained models compared to actual GI50 values. Significance of accurate predictions
determined by binomial test. ER = Error Rate
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gene signatures of doxorubicin sensitivity derived from
human or canine cell lines are able to separate sensitive
and resistant tumor samples. These data suggest that hu-
man data can be predictive of canine data and that both
human and canine cancer cell line data have predictive
potential for canine osteosarcoma.
Predictivity of human-based COXEN models on chemo-
sensitivity in canine cancer cell lines
Before we developed models to predict clinical outcome
in osteosarcoma patients, we evaluated how effective hu-
man COXEN models could predict DOX and CARBO
sensitivity in canine cancer cell lines. The best NCI60
models for the prediction of FACC cells involved col-
lapsing the microarray data to the gene level using the
max variance method. The 12 most sensitive and resist-
ant NCI60 lines were used as the training set and the 6
most and least sensitive cell lines in the FACC panel
were used as the test set. Models with NCI60-derived
genes that were co-expressed with the FACC and trained
solely on the NCI60 panel were 83 % accurate in pre-
dicting DOX sensitivity in the FACC (p = 0.0193, bino-
mial test) (Fig. 2c). In contrast, the NCI60-trained
models were only 58 % accurate in predicting CARBO
sensitivity in the FACC (p = 0.3872, binomial test)
(Fig. 2d). Although the canine test set was involved in
the co-expression step, the results of our DOX models
are encouraging that interspecies prediction modeling is
possible between human and canine cancer.
Predictivity of cell line-trained COXEN models on clinical
outcome in 33 independent canine osteosarcoma patients
Our next step was to compare the ability of cell line-
trained prediction models to accurately predict clinical
outcome in an independent canine osteosarcoma tumor
dataset (COS33). Sample information for the COS33
tumor panel is provide in Additional file 4: Table S3. In-
dividual reference sets used in the different models in-
cluded human and canine cancer cell line panels
containing multiple tumor types (NCI60, FACC) as well
as osteosarcoma-only subsets from the GDSC and FACC
panels (GDSCosteo, FACCosteo). After DEGs for DOX
or CARBO were identified in the reference set,they were
further filtered based on co-expression analysis with a
canine osteosarcoma tumor panel COS16 (Table 1).
Models were then trained on the corresponding refer-
ence set and tested independently on the COS33 tumor
panel. Data from a historic cohort study of 470 dogs
treated for osteosarcoma [37] were used to determine
cutoffs between “responders” and “non-responders” in
both canine osteosarcoma tumor datasets based on me-
dian disease free interval of dogs that received doxorubi-
cin (276 days) or carboplatin (296 days). The original
cutoffs for the COS16 panel reported by O’Donoghue et
al. fit within our definition of “responders” and “non-re-
sponders”, so no adjustments to group classification
needed to be made [31]. All of our modeling results are
reported in Additional file 5: Table S4, with error rates
based on external validation in the test set. The NCI60
model had an error rate of 0.3182 compared to 0.3043
for the FACC model (p = 0.0669 and 0.0466, binomial)
(Additional file 5: Table S4). However, the NCI60 model
resulted in better curve separation of predicted re-
sponders and non-responders compared to the FACC
model in the survival curve analysis (Additional file 5:
Table S4, Fig. 3a).
We then tested if modeling could be improved if we
used osteosarcoma-only cell line panels to better reflect
the test set by using the FACCosteo and GDSCosteo
datasets. Interestingly, we observed that human osteo-
sarcoma cell line model for DOX performed poorly with
an error rate of 0.4348 (p = 0.3388), whereas the FAC-
Costeo model for DOX was equally accurate to the
FACC model with an error rate of 0.3043 (p = 0.0466, bi-
nomial) (Additional file 5: Table S4). Improvement of
curve separation was observed in the survival curve ana-
lysis using the FACCosteo model, although only ap-
proaching significance (p = 0.0706, Fig. 3c).
NCI60 and FACC models of CARBO had error rates
of 0.4800 and 0.3462 in predicting sensitivity in the
COS33 (p = 0.500 and 0.0843, Additional file 5: Table S4
and Fig. 3b & d). The FACCosteo model was signifi-
cantly accurate with an error rate of 0.3077 (p =0.0378),
however in the survival curve analysis the FACC model
was superior to the FACCosteo model (p = 0.0482 versus
0.9038, Log Rank) (Additional file 5: Table S4, Fig. 3d).
A human osteosarcoma cell line model could not be per-
formed due to absence of available CARBO sensitivity
data in the GDSC panel. These data continue to suggest
that CARBO models performed best when trained with
canine cell line data.
Predictivity of tumor-trained models on clinical outcome
of 33 independent canine osteosarcoma patients
A study in 2010 introduced the use of “in vivo COXEN”
which implemented cell line panels for the reference set
but tumor panels for the model training set [14]. We
tested whether using the COS16 as the model training
set would improve our human and/or dog COXEN
models for DOX or CARBO in the COS33. The human
NCI60 DOX model that was co-expressed and trained
on the COS16 performed very well with an error rate of
0.2727 (p = 0.0262, binomial) and a very significant
separation of survival curves (p = 0.0010, Log Rank)
(Additional file 5: Table S4, Fig. 4a). Additionally, the
prediction scores significantly correlated with disease
free interval in a Cox proportional hazards regression
analysis with a hazard ratio of 0.03073 and a p-value of
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0.00695 (Additional file 5: Table S4). In contrast, A
human osteosarcoma cell line DOX model trained on
the COS16 performed poorly with an error rate of
0.4783 (p = 0.5000, binomial) (Additional file 5: Table
S4).
The canine FACC DOX model that was co-expressed
and trained on the COS16 performed well but to a lesser
extent with an error rate of 0.3043 (p = 0.0466, binomial),
and a separation of survival curves that approached signifi-
cance (p = 0.0714, Log Rank) (Additional file 5: Table S4,
Fig. 4c). The FACCosteo DOX model that was trained on
COS16 did not perform as well, with an error rate of
0.3913 (p = 0.2024) (Additional file 5: Table S4). These data
show that implementing an “in vivo COXEN” method did
result in our best human DOX model, and a canine DOX
model that performed slightly under the best-performing
FACCosteo cell line-trained model, suggesting it to be an
advantageous strategy.
The human NCI60 CARBO model trained on the
COS16 performed poorly with non-significant results
and an error rate of 0.4000 (Additional file 5: Table S4,
Fig. 4b). Both the canine FACC and FACCosteo CARBO
models trained on the COS16 had significant accuracies
with a shared error rate of 0.307 (p = 0.0378, binomial).
However, none of the other tests for model performance
were significant (Additional file 5: Table S4, Fig. 4d),
showing that although the CARBO models were gener-
ally less accurate compared to DOX models, canine
CARBO models consistently outperformed human
CARBO models in our studies.
Fig. 3 Cell line-trained models on clinical outcome in canine osteosarcoma patients treated with doxorubicin and/or carboplatin. a & b Analysis
comparing the survival curves of COS33 patients predicted to respond or not respond to doxorubicin (n = 22) (a) or carboplatin (n = 25) (b) from
a NCI60-trained model with the COS16 tumor panel used as the co-expression set. c Survival analysis of predicted responders and non-responders in the
COS33 to doxorubicin from a model trained on the osteosarcoma cell line subset of the FACC panel, with the COS16 used for co-expression. d Survival
analysis of predicted responders and non-responders in the COS33 to carboplatin from a FACC-trained model co-expressed with the COS16. Significant
difference in disease free interval between predicted groups was determined by Log Rank test
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Effect of COXEN models on clinical outcome of
osteosarcoma patients receiving combination chemotherapy
The best models each for DOX and CARBO were se-
lected based on overall performance from statistical
testing (Table 2). For DOX, the NCI60 model that was
co-expressed and trained on the COS16 was selected.
Probeset matching between species was done using the
best sequence homology method. Four genes are in-
volved in the model: Choline kinase alpha (CHKA),
Transducin-like enhancer of split 1 (E(sp1)homolog,Dro-
sophila) (TLE1), Eukaryotic translation initiation factor 6
(EIF6), and Testis derived transcript (3 LIM domains)
(TES). CHKA is involved in phospholipid biosynthesis
and tumor cell growth. TLE1 is a transcriptional co-
repressor known to inhibit NF-kappa-B expression and
WNT signaling. EIF6 and TES both are involved with
the cytoskeleton, EIF6 helps link ITGBB4 to the cyto-
skeleton, and TES is a scaffold protein that has roles in
cell adhesion, cell spreading, reorganization of the actin
cytoskeleton, regulates cell proliferation, and may act as
a tumor suppressor (Table 2).
For CARBO, the FACC model that was co-
expressed with the COS16 but trained back on the
FACC was selected. Six genes are involved in the
model: Oculocutaneous albinism II (OCA2), Hairy
and enhancer of split 3 (Drosophila) (HES3), unchar-
acterized cytochrome C oxidase (LOC100688725),
Proteasome (prosome, macropain) 26 s subunit, non-
ATPase, 3 (PSMD3), cOR4F25 olfactory receptor fam-
ily 4 subfamily F-like (cOR4F25), and transmembrane
protein 131-like (KIAA0922). OCA2 is a transporter
of tyrosine within melanocytes. HES3 is a transcrip-
tional repressor of gene requiring bHLH protein for
transcription. LOC100688725 has cytochrome C oxi-
dase activity. PSMD3 is involved in ATP-dependent
degradation of ubiquinated proteins. cOR4F25 is
Fig. 4 Tumor-trained models on clinical outcome in canine osteosarcoma patients treated with doxorubicin and/or carboplatin. a & b Analysis
comparing the survival curves of COS33 patients predicted to respond or not respond to doxorubicin (n = 22) (a) or carboplatin (n = 25) (b) from
models where genes identified from the NCI60 panel were co-expressed and trained on the COS16 tumor panel. c & d Survival analysis of predicted
responders and non-responders to doxorubicin (c) or carboplatin (d) of COS33 patients from models where genes identified from the FACC panel
were co-expressed and trained on the COS16 tumor panel. Significant difference in disease free interval between predicted groups was determined by
Log Rank test
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involved in canine olfactory processes. KIAA0922 is
an integral transmembrane protein with possible in-
volvement in immune responses (Table 2).
Fifteen dogs from the COS33 panel received com-
bination therapy of DOX and CARBO. Survival
curves from dogs who received combination treat-
ment were split into 4 groups and compared: dogs
predicted to be sensitive to neither drug, dogs pre-
dicted to be sensitive to only CARBO, dogs pre-
dicted to be sensitive to only DOX, and dogs
predicted to be sensitive to DOX and CARBO. In
Fig. 5a a significant trend was observed between the
curves, with the DOX only sensitive and DOX and
CARBO sensitive groups surviving disease-free much
longer than the CARBO only sensitive and resistant
groups (p = 0.0032, Log Rank trend). These data
show that dogs predicted to be sensitive to only
DOX or both DOX and CARBO lived longer disease
free than dogs predicted to be sensitive to CARBO
or neither drug.
Table 2 Genes from the best COXEN models for predicting clinical response to doxorubicin and carboplatin in the COS33
Model Gene symbol Gene title Function
Doxorubicin model
NCI60-COS16-COS16-COS33
CHKA Choline kinase alpha Phospholipid biosynthesis, tumor cell growth
TLE1 Transducin-like enhancer of split 1 (E(sp1)
homolog, Drosophila)
Transcriptional co-repressor; inhibits NF-kappa-B
expression and WNT signaling
EIF6 Eukaryotic translation initiation factor 6 Helps ITGBB4 link to cytoskeleton
TES Testis derived transcript (3 LIM domains) Scaffold protein; role in cell adhesion, cell spreading,
reorganization of actin cytoskeleton, regulates cell
proliferation, may act as a tumor suppressor
Carboplatin model
FACC-COS16-FACC-COS33
OCA2 Oculocutaneous albinism II Transporter of tyrosine within the melanocyte, may
determine eye and skin color
HES3 Hairy and enhancer of split 3 (Drosophila) Transcriptional repressor of genes that require bHLH
protein for their transcription
LOC100688725 Uncharacterized Cytochrome C oxidase Cytochrome C oxidase activity
PSMD3 Proteasome (prosome, macropain)
26 s subunit, non-ATPase, 3
Involved in ATP-dependent degradation of ubiquinated
proteins
cOR4F25 cOR4F25 olfactory receptor family 4 subfamily
F-like
Involved in canine olfactory system
KIAA0922 Transmembrane protein 131-like Integral transmembrane protein, possible involvement
in immune responses
Fig. 5 Effects of prediction-matched treatments on clinical outcome in canine osteosarcoma patients treated with doxorubicin and/or carboplatin.
a Survival analysis of 15 COS33 dogs receiving doxorubicin/carboplatin combination treatment separated into four prediction groups based on
the best performing doxorubicin and carboplatin models. Significant differences in curves determined by Log Rank trend test. b Survival analysis
between COS33 dogs (n = 32) that were treated with a drug our best performing models predicted them to be sensitive to (“COXEN matched”)
and dogs that were not (“COXEN mismatched”). For dogs that received combination treatment, a sensitive prediction on either the doxorubicin
or carboplatin model was needed to be a COXEN match. Significant difference in disease free interval between the curves was determined by
Log Rank test
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Effect of COXEN-matching on clinical outcome of canine
osteosarcoma patients receiving single agent or combination
treatment
In order to more fully evaluate the benefit of this gen-
omic approach of gene expression models to determine
treatment in canine osteosarcoma, we classified our
COS33 patients into two categories: “COXEN matched”
and “COXEN mismatched”. We evaluated patient out-
come if they actually received the specific treatment our
COXEN models indicated. Our criteria for classification
are detailed as follows: For patients treated only with
DOX, if the DOX model predicted them to be sensitive
(model score > 0.5), they were considered “COXEN
matched”. For patients treated only with CARBO, if the
CARBO model score > 0.5 they were considered “COXEN
matched”. For patients receiving a combination of DOX
and CARBO, both the DOX model and CARBO model
score needed to be > 0.5 for them to be considered
“COXEN matched”.
A survival curve analysis comparing the two groups
showed that a larger percentage of COXEN matched dogs
survived disease-free at all time points than COXEN mis-
matched dogs (p = 0.0006, Log Rank) (Fig. 5b). When the
combination treated dogs were excluded from the
analysis, COXEN matched dogs survived longer dis-
ease free than COXEN mismatched dogs (p = 0.0088,
Log Rank) (Additional file 6: Figure S2A). Addition-
ally, When the criteria for combination treated dogs
was relaxed to consider them to be COXEN matched
if they were predicted to be sensitive to at least one
of the two drugs, COXEN matched dogs continued to
survive longer disease free than dogs whose treatment
did not match COXEN predictions (p = 0.003, Log
Rank) (Additional file 6: Figure S2B).
We analyzed the strength of our COXEN modeling as
a factor associated with DFI by performing a univariate
Cox proportional hazards regression analysis with
“COXEN model treatment match” as a covariate to be
compared with six other clinical factors: Proximal hu-
meral tumor location, serum alkaline phosphatase levels
(ALP), monocyte count, lymphocyte count, body weight,
and age at diagnosis. COXEN model treatment match
was the only factor significantly associated with DFI in
the univariate analysis (p = 0.0353) (Additional file 7:
Table S5). Four of the seven factors with p-values less
than 0.25 (COXEN model treatment match, age at diag-
nosis, body weight, and proximal humeral tumor) were
than subjected to multivariate analysis followed by step-
wise forwards and backwards regression modeling to de-
termine the best subset of factors in final model. We
found that COXEN model treatment match had a haz-
ard ratio of 0.3102 which was significant (p = 0.0124).
The other significant factor associated with DFI in our
COS33 patients was body weight (hazard ratio = 1.0047,
p = 0.0261). The last factor in the model was proximal
humeral tumor location (hazard ratio = 2.3974, p = 0.0877).
Age at diagnosis fell out of the model after stepwise regres-
sion (Table 3).
Taken together, our studies suggest that gene expres-
sion models for drug sensitivity have great potential to
be used in an inter- and intraspecies manner for im-
provement of personalized medicine for canine osteosar-
coma patients.
Discussion
The use of gene expression prediction models in person-
alized medicine is emerging as a potential alternative to
traditional treatment strategies. In this study we were
able to successfully develop prediction models for DOX
or CARBO sensitivity in canine osteosarcoma using both
a combination of human and canine datasets as well as
canine datasets alone. The best performing DOX model
was developed by first identifying DEGs from the human
NCI60 panel, followed by co-expression and model
training on canine osteosarcoma tumors. The ability for
the COXEN method to extrapolate data from one data-
set to another was able to not only be applied from an
in vitro panel to an in vivo dataset, but also from one
species to another. Additionally, knowing the NCI60
panel does not contain osteosarcoma cell lines makes
this model even more impressive. These results have ex-
citing implications, as it suggests that it may be feasible
and beneficial to incorporate human genomic data in
the development of gene expression-based predictions of
treatment for canine cancer. This would be very advan-
tageous for canine oncology, because available data
needed for these types of analyses are currently much
more prevalent in human research.
Although the genes in our models do not have obvious
mechanisms that might influence drug sensitivity, it is
interesting that CHKA in our DOX model has recently
been shown to play a role in the sensitivity of human
ovarian cancer cells to DOX, paclitaxel, and cisplatin
[38]. Additionally, PSMD3 from our CARBO model was
identified as differentially expressed in human cancer
cell lines that were sensitive or resistant to the EGFR in-
hibitor lapatanib [39].
In general, attempts at building prediction models for
CARBO sensitivity were not as successful as they were
Table 3 Factors associated with disease free interval of COS33
patients in a multivariate analysis
Variable HR (95 % CI) P value
COXEN model treatment match 0.3102 (0.1240–0.7762) 0.0124
Body weight (continuous) 1.0047 (1.0052–1.0857) 0.0261
Proximal humeral tumor 2.3974 (0.8787–6.5407) 0.0877
HR hazard ratio, CI confidence interval, P values < 0.05 are in bold
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for DOX. Additionally, models developed using only ca-
nine datasets for CARBO did consistently better than
when the human NCI60 panel was incorporated in the
process. A possible explanation for this was that the
range of GI50 values in the NCI60 was the narrowest for
CARBO compared to DOX and CIS, suggesting that
genetic differences between “sensitive” and “resistant”
groups in the CARBO data may have been minimal or
were dominated by unrelated factors (Fig. 2a).
There are some limitations to this study that need to
be addressed before this type of method could conceiv-
ably be implemented in the clinic. First, the relatively
small sizes of our datasets made it difficult to reach sta-
tistically significant predictive power in many of our
modeling iterations.. Even in instances where statistical
significance was achieved as was shown with the signifi-
cant trend between different prediction groups in
combination-treated dogs, a sample size of 15 is not
large enough for firm conclusions to be made clinically
(Fig. 5a). Ideally, larger panels would serve to more fully
represent the heterogeneous cancer population, leading
potentially to more robust models We hope to expand
the FACC panel in coming years through the establish-
ment of new tumor-derived cell lines as well as through
increased collaborations with other institutions.
Another area that needs further study is the
optimization of the cutoffs between “responders” and
“non-responders” in in vivo datasets. It is possible that
using a different cutoff besides the median DFI in a large
historical cohort may improve prediction model per-
formance. We have recently begun a prospective study
in dogs with spontaneous osteosarcoma where their
chemotherapy treatment post limb amputation of either
doxorubicin, carboplatin, or both will be determined
based on the results of our top prediction models pre-
sented in this current study. This prospective study is
planned to involve 100 dogs which will not only increase
our available tumor datasets for optimizing cutoffs but
will allow us the opportunity to address the issues of
cost and time needed for data generation which are im-
portant for patients. We have found that the dropping
price for gene expression profiling is reasonable and
turnaround time of less than a week can be achieved,
making this option a feasible one in the clinic. Testing
our models prospectively will help to test their robust-
ness, which we have not sufficiently done. Regardless of
the limitations, our best performing models for DOX
and CARBO did achieve statistically significant results in
a truly independent test set, which is very encouraging.
We used the MiPP algorithm in our LDA model build-
ing process, which is designed to select the most parsimo-
nious models without sacrificing predictive efficacy. There
are advantages and disadvantages to this. Smaller models
could allow for the development of gene expression-based
tests similar to ones used in breast cancer diagnosis or
even RTPCR protocols that would deliver quick results for
patients. However, there is the opinion that prediction
models with few genes tend to be less robust when tested
against multiple independent datasets. As our models
have only been tested in one independent test set, we can-
not at present know if they would hold up to validation
from additional datasets. In our investigations other model
building methods besides using LDA and MiPP were
employed, including principal component regression and
lasso regression, which resulted in larger gene models
than when we used MiPP. Unfortunately, these alternative
models failed to perform as well as our best MiPP models
(data not shown).
Other options for model building that might be ex-
plored in the future would be to adopt some machine
learning methods with the ability to incorporate multiple
types of genomic data into the modeling process. In
2014 an article reporting the results of a community-
based contest of 44 competing drug sensitivity predic-
tion algorithms concluded that although gene expression
microarrays was consistently the top source for predict-
ive power, performance could be improved with the
addition of data such as methylation status of genes,
copy number variation, and exome sequencing [40].
These additional types of genomic data would need to
be obtained for the datasets involved in the prediction
model process before these new strategies can be investi-
gated. Ultimately, we hope that success of this strategy
of personalized treatment in dogs could serve as much
needed validation for similar methods in human
research to move forward.
Conclusions
This study has shown that human and canine cancer cell
lines are similarly sensitive to chemotherapy and that
gene expression-based modeling using canine datasets
or a combination of human and canine datasets can ac-
curately predict clinical outcome in canine osteosarcoma
patients treated with adjuvant DOX and/or CARBO
therapy. These results are important for human and ca-
nine cancer research for two main reasons: First, it
shows the potential of an advanced animal translational
model for testing genomic methods of personalized can-
cer treatment in a clinical setting; second, it shows the
potential for canine cancer research to expand in this
genomic era through the incorporation of human gen-
omic data into their model development design, which is
currently much more prevalent and available than ca-
nine datasets.
Availability of data and materials
Gene expression data from Affymetrix Human Genome
U133A arrays and U133 Plus 2.0 arrays for the human
Fowles et al. BMC Bioinformatics  (2016) 17:93 Page 12 of 14
NCI-60 [11] and a panel of 16 canine osteosarcoma tu-
mors [31] were obtained publicly from NCBI’s Gene Ex-
pression Omnibus website (dataset # GSE5846,
GSE32474, and GSE24251, respectively). HT Human
Genome U133A array data from the Genomics of Drug
Sensitivity in Cancer (GDSC) panel was publicly avail-
able from the Array Express website (E-MTAB-783).
The gene expression data for the FACC and COS33
panels were generated and made available at NCBI's
Gene Expression Omnibus website (dataset # GSE76126
and GSE76127, respectively) (Table 1).
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